Several clinical trials have shown that A2AR antagonists ameliorate the dyskinesia induced by chronic L-DOPA treatment in PD patients (Pinna et al., 2005; Xu et al., 2005; Mizuno and Kondo, 2013) and it is possible that receptor silencing might be an alternative therapy to reduce receptors activity. This evidence concerns the gene ADORA2A and drug-induced dyskinesia.